Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “MEXICO”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1984

Placentas of small-for-dates infants: a small controlled series from Mexico City, Mexico.

Thirty-five placentas of small-for-dates infants were compared with control placentas of normally grown infants. They were small by weight, area, and volume and tended to have a marginal cord insertion; marginal cord insertion was associated with a thick cord, and central insertion, with a thin cord. When the two groups were compared, the first showed increased fibrinoid deposits and atherosis, more severe fetal abnormalities, and abnormal nutrition in the mother, together with a high incidence of preeclampsia. In the mothers of both groups, peak diastolic blood pressure was lower than that in the control group; additional factors leading to a probable reduction in placental blood flow were different in the two groups.

Female↗
PubMed2005

WHO informal consultation on quality, safety and efficacy specifications for live attenuated rotavirus vaccines Mexico City, Mexico, 8-9 February 2005.

Rotavirus vaccines are at an advanced stage of development but there are as yet no WHO recommendations on production and quality control to provide regulatory guidance. A meeting of experts was convened by WHO and PAHO/AMRO to review the scientific basis for production and quality control of rotavirus vaccines, and to discuss specific measures to assure the safety and efficacy of rotavirus vaccines. The meeting was attended by 25 experts from 14 countries, drawn from academia, public health, national regulatory authorities and vaccine producers. It was agreed that existing guidance for other live virus vaccines provides a very good basis for product characterization, especially for source materials and control of production. The basis for attenuation of current vaccines or vaccine candidates is not known but, at least for the vaccines based on the Jennerian approach of using animal (bovine) rotaviruses, is likely to be multigenic. The risk of intussusception in humans is influenced by genetic background and age. Recent analyzes of large vaccine safety trials found that certain strains of vaccine virus were not associated with intussusception, although in these trials the first dose of vaccine was not administered to children over 3 months of age. Since age is a risk factor for intussusception, this may suggest that early delivery of the first dose of vaccine is desirable. However, maternal antibodies may mitigate against early delivery of the first vaccine dose. Factors which could affect vaccine efficacy or safety include strain diversity, malnutrition, other enteric infections, parasitic infection or immune suppression. It was concluded that data from clinical trials conducted in one part of the world would not necessarily be predictive of vaccine efficacy in other places. It was agreed that in nonclinical evaluations there was a need to use oral dosing for toxicity studies and, because rotavirus is non-neurovirulent, that there was no need for an animal neurovirulence test. For clinical evaluations there was a need for a standard definition of severe disease as the clinical endpoint, a need for studies in diverse geographical regions, and the need to control for possible interference by factors such as other oral vaccinations, intercurrent infections and breast feeding. There is no accepted correlate of protection. Secretory IgA is the most satisfactory laboratory parameter currently available and for a period after vaccination much of the specific serum IgA is of this type, so that serum IgA levels can act as measure of seroconversion. The need for standardization of the potency assay for release of vaccine was identified, as was a need to develop guidance on standardized approaches to post-marketing surveillance for rotavirus vaccines.

Mexico↗
PubMed2003

Carbonyl levels in indoor and outdoor air in Mexico City and Xalapa, Mexico.

Carbonyl compounds in air were measured at two houses, three museums, and two offices. All sites lacked air-conditioning systems. Although indoor and outdoor air was measured simultaneously at each site, the sites themselves were sampled in different dates. Mean concentrations were higher in indoor air. Outdoor means concentrations of acetone were the highest in all sites, ranging from 12 to 60 microg m(-3). In general, formaldehyde and acetaldehyde had similar mean concentrations, ranging from 4 to 32 and 6 to 28 microg m(-3), respectively. Formaldehyde and acetone mean indoor concentrations were the highest, ranging from 11 to 97 and 17 to 89 microg m(-3), respectively, followed by acetaldehyde with 5 to 47 microg m(-3). Formaldehyde and acetaldehyde had the highest mean concentration in the offices where there were smokers. Propionaldehyde and butyraldehyde concentrations did not show definite differences between indoor and outdoor air. In general, the highest outdoor and indoor hourly concentrations were observed from 10:00 to 15:00 h. Mean indoor/outdoor ratios of carbonyls exceeded 1. Formaldehyde and acetaldehyde risks were higher in smoking environments.

Air Pollutants↗
PubMed2004

Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico.

We determined the prevalence of hepatitis C virus (HCV) in hemodialysis patients by antibody testing and HCV RNA determination by PCR. A total of 149 patients with kidney failure with replacement therapy were tested. The prevalence of anti-HCV was 6.7% (10 of 149 patients), and viremia was detectable in 8 of 149 (5%) patients. Three of 149 patients (2%) were anti-HCV negative with detectable HCV RNA.

Hepatitis C↗